...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trillium
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Thanks kbc for straightening me out on expectations.

I would have thought that a cancer drug that can extend the length of effectiveness of numerous existing cancer therapies would have had some value.

I have no interest in a CVR at $1.

Cheers

Toinv

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply